Effect of the Premalignant and Tumor Microenvironment on Immune Cell Cytokine Production in Head and Neck Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2014 Apr 5

PMID 24698959

Citations 37

Authors

Sara D Johnson

Anna-Maria A De Costa

M Rita I Young

Affiliations

Soon will be listed here.

Abstract

Head and neck squamous cell carcinoma (HNSCC) is marked by immunosuppression, a state in which the established tumor escapes immune attack. However, the impact of the premalignant and tumor microenvironments on immune reactivity has yet to be elucidated. The purpose of this study was to determine how soluble mediators from cells established from carcinogen-induced oral premalignant lesions and HNSCC modulate immune cell cytokine production. It was found that premalignant cells secrete significantly increased levels of G-CSF, RANTES, MCP-1, and PGE2 compared to HNSCC cells. Splenocytes incubated with premalignant supernatant secreted significantly increased levels of Th1-, Th2-, and Th17-associated cytokines compared to splenocytes incubated with HNSCC supernatant. These studies demonstrate that whereas the premalignant microenvironment elicits proinflammatory cytokine production, the tumor microenvironment is significantly less immune stimulatory and may contribute to immunosuppression in established HNSCC.

Citing Articles

CPA4 as a biomarker promotes the proliferation, migration and metastasis of clear cell renal cell carcinoma cells.

Wang K, Ding Y, Liu Y, Ma M, Wang J, Kou Z J Cell Mol Med. 2024; 28(7):e18165.

PMID: 38494845 PMC: 10945090. DOI: 10.1111/jcmm.18165.

NUDT21 interacts with NDUFS2 to activate the PI3K/AKT pathway and promotes pancreatic cancer pathogenesis.

Huang X, Chen Y, Tian L, Du L, Cheng X, Lu Y J Cancer Res Clin Oncol. 2024; 150(1):8.

PMID: 38195952 PMC: 10776698. DOI: 10.1007/s00432-023-05540-1.

Chronic oxidative stress adaptation in head and neck cancer cells generates slow-cyclers with decreased tumour growth in vivo.

Berner J, Miebach L, Kordt M, Seebauer C, Schmidt A, Lalk M Br J Cancer. 2023; 129(5):869-883.

PMID: 37460712 PMC: 10449771. DOI: 10.1038/s41416-023-02343-6.

MCM10: An effective treatment target and a prognostic biomarker in patients with uterine corpus endometrial carcinoma.

Chen J, Wu S, Wang J, Han C, Zhao L, He K J Cell Mol Med. 2023; 27(12):1708-1724.

PMID: 37246638 PMC: 10273062. DOI: 10.1111/jcmm.17772.

Epigenetically programmed resistance to chemo- and immuno-therapies.

Walker R, Rentia Z, Chiappinelli K Adv Cancer Res. 2023; 158:41-71.

PMID: 36990538 PMC: 10184181. DOI: 10.1016/bs.acr.2022.12.001.

References

Young M, Wright M, Lozano Y, Prechel M, Benefield J, Leonetti J . Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells. Int J Cancer. 1997; 74(1):69-74. DOI: 10.1002/(sici)1097-0215(19970220)74:1<69::aid-ijc12>3.0.co;2-d. View

Hambek M, Baghi M, Wagenblast J, Schmitt J, Baumann H, Knecht R . Inverse correlation between serum PGE2 and T classification in head and neck cancer. Head Neck. 2006; 29(3):244-8. DOI: 10.1002/hed.20503. View

Ogino T, Shigyo H, Ishii H, Katayama A, Miyokawa N, Harabuchi Y . HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res. 2006; 66(18):9281-9. DOI: 10.1158/0008-5472.CAN-06-0488. View

Chikamatsu K, Sakakura K, Whiteside T, Furuya N . Relationships between regulatory T cells and CD8+ effector populations in patients with squamous cell carcinoma of the head and neck. Head Neck. 2006; 29(2):120-7. DOI: 10.1002/hed.20490. View

Grandis J, Falkner D, Melhem M, Gooding W, Drenning S, Morel P . Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences. Clin Cancer Res. 2000; 6(7):2794-802. View

Linkov F, Lisovich A, Yurkovetsky Z, Marrangoni A, Velikokhatnaya L, Nolen B . Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiol Biomarkers Prev. 2007; 16(1):102-7. DOI: 10.1158/1055-9965.EPI-06-0602. View

Forastiere A, Koch W, Trotti A, Sidransky D . Head and neck cancer. N Engl J Med. 2002; 345(26):1890-900. DOI: 10.1056/NEJMra001375. View

Young M, Wright M, Lozano Y, Matthews J, Benefield J, Prechel M . Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int J Cancer. 1996; 67(3):333-8. DOI: 10.1002/(SICI)1097-0215(19960729)67:3<333::AID-IJC5>3.0.CO;2-S. View

Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, Agueznay N . Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res. 2006; 12(2):465-72. DOI: 10.1158/1078-0432.CCR-05-1886. View

10.

Cho Y, Yoon H, Lee J, Hong S, Hong S . Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol. 2011; 47(12):1148-53. DOI: 10.1016/j.oraloncology.2011.08.007. View

11.

Badoual C, Sandoval F, Pere H, Hans S, Gey A, Merillon N . Better understanding tumor-host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies. Head Neck. 2010; 32(7):946-58. DOI: 10.1002/hed.21346. View

12.

MacKenzie K, Clark K, Naqvi S, McGuire V, Noehren G, Kristariyanto Y . PGE(2) induces macrophage IL-10 production and a regulatory-like phenotype via a protein kinase A-SIK-CRTC3 pathway. J Immunol. 2012; 190(2):565-77. PMC: 3620524. DOI: 10.4049/jimmunol.1202462. View

13.

Pak A, Wright M, Matthews J, Collins S, Petruzzelli G, Young M . Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin Cancer Res. 1995; 1(1):95-103. View

14.

Almand B, Clark J, Nikitina E, Van Beynen J, English N, Knight S . Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2000; 166(1):678-89. DOI: 10.4049/jimmunol.166.1.678. View

15.

Smith C, Chen Z, Dong G, Loukinova E, Pegram M, Van Waes C . The host environment promotes the development of primary and metastatic squamous cell carcinomas that constitutively express proinflammatory cytokines IL-1alpha, IL-6, GM-CSF, and KC. Clin Exp Metastasis. 1999; 16(7):655-64. DOI: 10.1023/a:1006559811429. View

16.

Lathers D, Achille N, Young M . Incomplete Th2 skewing of cytokines in plasma of patients with squamous cell carcinoma of the head and neck. Hum Immunol. 2003; 64(12):1160-6. DOI: 10.1016/j.humimm.2003.08.024. View

17.

Wahl S, Wen J, Moutsopoulos N . TGF-beta: a mobile purveyor of immune privilege. Immunol Rev. 2006; 213:213-27. DOI: 10.1111/j.1600-065X.2006.00437.x. View

18.

Tsuzuki H, Fujieda S, SUNAGA H, Noda I, Saito H . Expression of granulocyte colony-stimulating factor receptor correlates with prognosis in oral and mesopharyngeal carcinoma. Cancer Res. 1998; 58(4):794-800. View

19.

Whiteside T . Immunobiology of head and neck cancer. Cancer Metastasis Rev. 2005; 24(1):95-105. DOI: 10.1007/s10555-005-5050-6. View

20.

Mann E, Spiro J, Chen L, Kreutzer D . Cytokine expression by head and neck squamous cell carcinomas. Am J Surg. 1992; 164(6):567-73. DOI: 10.1016/s0002-9610(05)80708-1. View